58-WEEK OPEN-LABEL TRIAL OF TAVAPADON IN PARKINSON'S DISEASE (TEMPO-4 TRIAL)

This clinical research project is an open-label clinical investigation spanning 58 weeks that evaluates tavapadon, an investigational compound, in people diagnosed with Parkinson’s disease.

The TEMPO-4 Trial contributes to evidence about tavapadon’s performance in a Parkinson’s disease population over an extended period. Open-label trials commonly serve to gather real-world tolerability and adherence data, to provide continued access to investigational therapy following blinded studies or to explore longer-term safety and effectiveness in broader or more representative populations.
 This project will advance potential contributions to Parkinson’s disease therapeutics.